The H374R mutation is also associated with recurrent PGL, suggesting a crucial role for PHD2/EGLN1 as a tumor suppressor gene that is similar to VHL missense mutations seen in type 2 VHL disease, i.e., high risk of PCC/PGL (97). This evidence concerns the gene EGLN1 and neoplasm.